Home
About Us
Meet the Team
Scientific Advisors
Research Focus
Our Focus: CD34+ Cell Replacement
Pipeline
Parkinson’s disease
Alzheimer’s Disease
Blood and Immune Rejuvenation
Rare disease targets
Resources
Corporate Presentation
Scientific Publications
Patent Portfolio
News
Contact Us
Resources
Scientific Publications
Non-toxic HSC Transplantation-Based Macrophage/Microglia-Mediated GDNF Delivery for Parkinson's Disease.
Mol Ther Methods Clin Dev. 2020 Jun 12;17:83-98.
PMID: 31890743; PMCID: PMC6931095
Mobilization-based transplantation of young-donor hematopoietic stem cells extends lifespan in mice.
Aging Cell. 2020 Mar;19(3):e13110.
PMID: 32012439; PMCID: PMC7059148
Lentiviral Infection of Mouse Bone Marrow Cells for Hematopoietic Stem Cell Transplantation.
Methods Mol Biol. 2019;1919:205-213.
PMID: 30656632
Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease.
Stem Cells Dev. 2018 Jul 15;27(14):995-1005.
PMID: 29562865
GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice.
Sci Rep. 2018 Apr 3;8(1):5460.
PMID: 29615705; PMCID: PMC5882968
Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR-/- mice.
Gene Ther. 2016 Jan;23(1):78-85.
PMID: 26204499; PMCID: PMC4939901
Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Neurosci Lett. 2013 Feb 22;535:24-9.
PMID: 23295906; PMCID: PMC3645298
Evaluation of macrophage-specific promoters using lentiviral delivery in mice.
Gene Ther. 2012 Nov;19(11):1041-7.
PMID: 22130447; PMCID: PMC3697098
Macrophage LXRα gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-/-) mice.
Gene Ther. 2011 Aug;18(8):835-41.
PMID: 21390069
Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.
Mol Ther. 2010 Aug;18(8):1536-44.
PMID: 20531393; PMCID: PMC2927058
Development of a synthetic promoter for macrophage gene therapy.
Hum Gene Ther. 2006 Sep;17(9):949-59.
PMID: 16972763
Critical flanking sequences of PU.1 binding sites in myeloid-specific promoters.
J Biol Chem. 1999 Nov 5;274(45):32453-60.
PMID: 10542290
PU.1 is essential for p47(phox) promoter activity in myeloid cells.
J Biol Chem. 1997 Jul 11;272(28):17802-9.
PMID: 9211934
Home
About Us
Research Focus
Resources
News
Contact Us
© 2020 HemaCure, inc. All rights reserved.
close
chevron-down
bars